Guia Clínica de l'HIV 2003 - Sida Studi

coll.qxd 4/03/03 06:05 Página 44236. Safety and toxicity of individual antiretroviral agents in pregnancy - Updated2002.37. Public Health Service Task Force Recommendations for the Use of AntiretroviralDrugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventionsto reduce Perinatal HIV-1 Transmission in the United States. MMWR2002.38. Watts, D.H. Management of human immunodeficiency virus infection in pregnancy.N Engl J Med 2002; 346: 1879-1891.39. Lorenzi, P., Spicher, V.M., Laubereau, B. i cols. Antiretroviral therapies in pregnancy:Maternal, fetal and neonatal effects. AIDS 1998; 12: F241-F247.40. Connor, E.M., Sperling, R.S., Gelber, R. i cols. Reduction of maternal-infanttransmission of human immunodeficiency virus type 1 with zidovudine treatment.N Engl J Med 1994; 331: 1173-1180.41. Combination antiretroviral therapy and duration of pregnancy: EuropeanColaborative Study, Swiss Mother and Child HIV Cohort Study. AIDS 2000;142913-142920.42. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testingas part of treatment management: Recommendations for the european setting.The Euroguidelines group for HIV resistence. AIDS 2001; 15: 309-320.43. Ioannidis, J.P., Abrams, E.J., Ammann, A. i cols. Perinatal transmission ofhuman immunodeficiency virus type 1 by pregnant women with RNA virusloads